Detection of Cerebral Metastases on Magnetic Resonance Imaging: Intraindividual Comparison of Gadobutrol with Gadopentetate Dimeglumine

References

• Kondziolka D, Patel A, Lunsford LD, Kassam A, Flickinger JC. Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys 1999; 45: 427–34
   PubMed Web of Science ®Google Scholar
• McDermott MW, Sneed PK. Radiosurgery in metastatic brain cancer. Neurosurgery 2005; 57(Suppl 5)S45–53
   PubMed Web of Science ®Google Scholar
• Kaal EC, Niel CG, Vecht CJ. Therapeutic management of brain metastasis. Lancet Neurol 2005; 4: 289–98
   PubMed Web of Science ®Google Scholar
• Schellinger PD, Meinck HM, Thron A. Diagnostic accuracy of MRI compared to CCT in patients with brain metastases. J Neurooncol 1999; 44: 275–81
   PubMed Web of Science ®Google Scholar
• Wen PY, Loeffler JS. Management of brain metastases. Oncology 1999; 13: 941–57
   PubMed Web of Science ®Google Scholar
• Healy ME, Hesselink JR, Press GA, Middleton MS. Increased detection of intracranial metastases with intravenous Gd-DTPA. Radiology 1987; 165: 619–24
   PubMed Web of Science ®Google Scholar
• Valk J, Algra PR, Hazenberg CJ, Slooff WBM, Slavand MG. A double-blind, comparative study of gadodiamide injection and gadopentetate dimeglumine in MRI of the central nervous system. Neuroradiology 1993; 35: 173–7
   PubMed Web of Science ®Google Scholar
• Åkeson P, Jonsson E, Haugen I, Holtas S. Contrast-enhanced MRI of the central nervous system: comparison between gadodiamide injection and gadolinium-DTPA. Neuroradiology 1995; 37: 229–33
   PubMed Web of Science ®Google Scholar
• Oudkerk M, Sijens PE, van Beek EJ, Kuijpers TJ. Safety and efficacy of Dotarem (Gd-DOTA) versus Magnevist (Gd-DTPA) in magnetic resonance imaging of the central nervous system. Invest Radiol 1995; 30: 75–8
   PubMed Web of Science ®Google Scholar
• Grossman RI, Rubin DI, Hunter G, Haughton VM, Lee D, Sze G, et al. Magnetic resonance imaging in patients with central nervous system pathology. A comparison of OptiMARK (Gd-DTPA-BMEA) and Magnevist (Gd-DTPA). Invest Radiol 2000; 35: 412–9
   PubMed Web of Science ®Google Scholar
• Greco A, Parker JR, Ratcliffe CG, Kirchin MA, McNamara MT. Phase III, randomized, double blind, crossover comparison of gadoteridol and gadopentetate dimeglumine in magnetic resonance imaging of patients with intracranial lesions. Australas Radiol 2001; 45: 457–63
   PubMedGoogle Scholar
• Yuh WTC, Fisher DJ, Runge VM, Atlas SW, Harms SE, Maravilla KR, et al. Phase III multicenter trial of high dose gadoteridol in MR evaluation of brain metastases. Am J Neuroradiol 1994; 15: 1037–51
   PubMed Web of Science ®Google Scholar
• Yuh WTC, Tali ET, Nguyen HD, Simonson TM, Mayr NA, Fisher DJ. The effect of contrast dose, imaging time and lesion size in the MR detection of intracerebral metastasis. Am J Neuroradiol 1995; 16: 373–80
   PubMed Web of Science ®Google Scholar
• Van Dijk P, Sijens PE, Schmitz PI, Oudkerk M. Gd-enhanced MR imaging of brain metastases: contrast as a function of dose and lesion size. Magn Reson Imaging 1997; 15: 535–41
   PubMed Web of Science ®Google Scholar
• Sze G, Johnson C, Kawamura Y, Goldberg SN, Lange R, Friedland RJ, et al. Comparison of single- and triple-dose contrast material in the MR screening of brain metastases. Am J Neuroradiol 1998; 19: 821–8
   PubMed Web of Science ®Google Scholar
• Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann HJ. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol 2005; 40: 715–24
   PubMed Web of Science ®Google Scholar
• Tombach B, Benner T, Reimer P, Schuierer G, Fallenberg EM, Geens V, et al. Do highly concentrated gadolinium chelates improve MR brain perfusion imaging? Intraindividually controlled randomized crossover concentration comparison study of 0.5 versus 1.0 mol/L gadobutrol. Radiology 2003; 226: 880–8
   PubMed Web of Science ®Google Scholar
• Thilmann O, Larsson E-M, Björkmann-Burtscher IM, Ståhlberg F, Wirestam R. Comparison of contrast agents with high molarity and with weak protein binding in cerebral perfusion imaging at 3T. J Magn Reson Imaging 2005; 22: 597–604
   PubMed Web of Science ®Google Scholar
• Schaefer FK, Schaefer PJ, Altjohann C, Bourne M, Decobelli F, Goyen M, et al. A multicenter, site-independent, blinded study to compare the diagnostic accuracy of contrast-enhanced magnetic resonance angiography using 1.0M gadobutrol (Gadovist) to intraarterial digital subtraction angiography in body arteries. Eur J Radiol 2007; 61: 315–23
   PubMed Web of Science ®Google Scholar
• Goyen M, Lauenstein T, Herborn C, Debatin J, Bosk S, Ruehm S. 0.5M Gd chelate (Magnevist) versus 1.0M Gd chelate (Gadovist): dose-independent effect on image quality of pelvic three-dimensional MR-angiography. J Magn Reson Imaging 2001; 14: 602–7
   PubMed Web of Science ®Google Scholar
• Tombach B, Benner T, Reimer P, Kisters K, Schaefer RM, Geens V, et al. Renal tolerance of a neutral gadolinium chelate (gadobutrol) in patients with chronic renal failure: results of a randomized study. Radiology 2001; 218: 651–7
   PubMed Web of Science ®Google Scholar
• Balzer JO, Loewe C, Davis J, Goyen M, Leiner T, Meaney JF, et al. Safety of contrast-enhanced MR angiography employing gadobutrol 1.0M as contrast material. Eur Radiol 2003; 13: 2067–74
   PubMed Web of Science ®Google Scholar
• Vogler H, Platzek J, Schumann-Giampieri G, Frenzel T, Weinmann HJ, Radüchel B, et al. Pre-clinical evaluation of gadobutrol: a new, neutral extracellular contrast agent for magnetic resonance imaging. Eur J Radiol 1995; 21: 1–10
   PubMed Web of Science ®Google Scholar
• Lemke, AJ, Sander, B, Balzer, T, Geens, V, Hosten, N, Felix, R. Safety and use of gadobutrol in patients with brain tumors (phase III trial). Rofo 1997;167:591–8, (in German).
   PubMedGoogle Scholar
• Hartmann, M, Forsting, M, Jansen, O, Albert, FK, Balzer, T, Sartor, K. Does the administration of a high dose of a paramagnetic contrast medium (Gadovist) improve the diagnostic value of magnetic resonance tomography in glioblastomas?. Rofo 1996;164:119–25, (in German).
   PubMedGoogle Scholar
• Vogl, TJ, Friebe, CE, Balzer, T, Mack, MG, Steiner, S, Schedel, H, , et al. Diagnosis of cerebral metastasis with standard dose gadobutrol vs. high dose protocol. Intraindividual evaluation of a phase II high dose study. Radiologe 1995;35:508–16, (in German).
   PubMed Web of Science ®Google Scholar
• Paek SH, Audu PB, Sperling MR, Cho J, Andrews DW. Reevaluation of surgery for the treatment of brain metastases: review of 208 patients with single or multiple brain metastases treated at one institution with modern neurosurgical techniques. Neurosurgery 2005; 56: 1021–34
   PubMed Web of Science ®Google Scholar
• Huppertz A, Rohrer M. Gadobutrol, a highly concentrated MR-imaging contrast agent: its physicochemical characteristics and the basis for its use in contrast-enhanced MR angiography and perfusion imaging. Eur Radiol 2004; 14(Suppl 5)M12–8
   PubMed Web of Science ®Google Scholar
• Pintaske J, Martirosian P, Graf H, Erb G, Lodemann KP, Claussen CD, et al. Relaxivity of gadopentetate dimeglumine (Magnevist), gadobutrol (Gadovist), and gadobenate dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla. Invest Radiol 2006; 41: 213–21
   PubMed Web of Science ®Google Scholar
• Knopp MV, Runge VM, Essig M, Hartman M, Jansen O, Kirchin MA, et al. Primary and secondary brain tumors at MR imaging: bicentric intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine. Radiology 2004; 230: 55–64
   PubMed Web of Science ®Google Scholar
• Colosimo C, Knopp MV, Barreau X, Gerardin E, Kirchin MA, Guezenoc F, et al. A comparison of Gd-BOPTA and Gd-DOTA for contrast-enhanced MRI of intracranial tumours. Neuroradiology 2004; 46: 655–65
   PubMed Web of Science ®Google Scholar
• Maravilla KR, Maldjian JA, Schmalfuss IM, Kuhn MJ, Bowen BC, Wippold FJ 2nd, et al. Multicenter, double-blind, randomized, intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine in MRI of the CNS. Radiology 2006; 240: 389–400
   PubMed Web of Science ®Google Scholar
• Kuhn MJ, Picozzi P, Maldjian JA, Schmalfuss IM, Maravilla KR, Bowen BC, et al. Evaluation of intra-axial enhancing brain tumors on magnetic resonance imaging: intra-individual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for visualization and assessment, and implications for surgical intervention. J Neurosurg 2007; 106: 557–6
   PubMed Web of Science ®Google Scholar